Skip to main content
Fig. 3 | BMC Public Health

Fig. 3

From: Range of invasive meningococcal disease sequelae and health economic application – a systematic and clinical review

Fig. 3

Number of IMD sequelae by category reported in A) each OS and B) each EE. AU: Australia; BE: Belgium; CA: Canada; CH: Switzerland; CZ: Czech Republic; DK: Denmark; EE: economic evaluation; EU: European Union; FR: France; GE: Germany; GR: Greece; IC: Iceland; IMD: invasive meningococcal disease; IR: Ireland; IS: Israel; IT: Italy; N.: number; NL: Netherlands; OS: observational study; PO: Poland; SE: Sweden; SL: Slovakia; SP: Spain; UK: United Kingdom; US: United States (of America) *Note: studies reporting number but not type of sequelae or grouping sequelae into a composite outcome. The number of sequelae reported per observational study (OS) and per health economic study (HES) categorised as physical, neurological or psychological/behavioural

Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us